Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder.
Journal of Medicinal Chemistry January 23, 2025 Allana Cristina Faustino Martins, Bretton Badenoch, Roberto da Silva Gomes 2 citations
Treatment-resistant depression responds quickly to ketamine. As an N-methyl-d-aspartate receptor (NMDAR) antagonist, ketamine may affect prefrontal cortex (PFC) neurons. Recent investigations reveal that the (R)-enantiomer is the most effective and least abuseable antidepressant. The Food and Drug Administration approves only the (S)-enantiomer for medical usage. (2R,6R)-Hydroxynorketamine...